• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations

  • Print
  • Share
  • E-mail

Patent and Exclusivity Search Results from query on Appl No 202611 Product 001 in the OB_Rx list.

Patent Data

Appl No Prod No Patent No Patent
Drug Substance
Drug Product
Patent Use
N202611 001 6346532 Oct 15, 2018 Y Y
N202611 001 6562375 Aug 1, 2020 Y
N202611 001 6699503 Sep 10, 2013 Y
N202611 001 7342117 Nov 4, 2023 Y
N202611 001 7750029 Dec 18, 2023 U - 913
N202611 001 7982049 Nov 4, 2023 Y
N202611 001 RE44872 Dec 18, 2023 U - 1527

Exclusivity Data

Appl No Prod No Exclusivity Code Exclusivity Expiration
N202611 001 NCE Jun 28, 2017

Additional information:

  1. Patents are published upon receipt by the Orange Book Staff and may not reflect the official receipt date as described in 21 CFR 314.53(d)(5).
  2. Patents listed prior to August 18, 2003 are flagged with method of use claims only as applicable and submitted by the sponsor. These patents may not be flagged with respect to other claims which may apply.

View a list of all patent use codes
View a list of all exclusivity codes

Return to Electronic Orange Book Home Page

FDA/Center for Drug Evaluation and Research
Office of Generic Drugs
Division of Labeling and Program Support
Update Frequency:

Orange Book Data - Monthly
Generic Drug Product Information & Patent Information - Daily
Orange Book Data Updated Through August 2014
Patent and Generic Drug Product Data Last Updated October 01, 2014